Buy Arbidol powder for oral suspension 25mg/5ml 37g in pharmacies
A homogeneous suspension of white or white with a yellowish or creamy tint of color with a characteristic fruity odor.
Treatment: 10 ml x 4 times a day, 5 days Post-exposure prophylaxis: 10 ml x 1 time a day, 10–14 days Seasonal prophylaxis: 10 ml x 2 times a week, 3 weeks
Composition and description
Active substance: 5 ml of suspension contains: umifenovir (umifenovir hydrochloride monohydrate – 25.88 mg), (in terms of umifenovir hydrochloride – 25.00 mg).
Excipients: Sodium chloride – 26.85 mg, maltodextrin (Kleptose Linecaps) – 750.00 mg, sucrose (sugar) – 840.42 mg, colloidal silicon dioxide (Aerosil) – 24, 60 mg, titanium dioxide – 25.00 mg, pregelatinized starch (type PA5PH) – 129.50 mg, sodium benzoate – 9.25 mg, banana flavor – 12.40 mg, cherry flavor – 6.10 mg.
Description: Granular powder of white or almost white color with a characteristic fruity odor.
Description of the prepared suspension: a homogeneous suspension of white or white with a yellowish or creamy tint of color with a characteristic fruity odor.
Release form: Powder for the preparation of suspension for oral administration, 25 mg/5 ml.
37 g in bottles with a capacity of 125 ml (with a mark to the level of 100 ml) of dark (amber) glass.
One bottle, along with instructions for use and a measuring spoon, is placed in a cardboard pack. Contraindications Hypersensitivity to umifenovir or any component of the drug.
Age up to 2 years; age up to 6 years (according to indications, nonspecific prevention of SARS); age up to 12 years (according to indications for treatment of SARS).
Sucrase/isomaltase deficiency, fructose intolerance, glucose-galactose malabsorption. Dosage 5 mg/ml Indications for use Prevention and treatment of influenza A and B, other acute respiratory viral infections in children over 2 years of age and adults; complex therapy of acute intestinal infections of rotavirus etiology in children from 2 years of age; — nonspecific prevention of severe acute respiratory syndrome (SARS) in children over 6 years of age and adults; treatment of severe acute respiratory syndrome (SARS) in children over 12 years of age and adults. Interaction with other drugs When prescribed with other drugs, no negative effects were noted. Overdose Not noted. pharmachologic effect
Pharmacological group: Antiviral agent.
Pharmacodynamics: Antiviral agent. Specifically suppresses in vitro influenza viruses A and B (Influenzavirus A, B), including highly pathogenic subtypes A(H1N1)pdm09 and A(H5N1), as well as other viruses that cause acute respiratory viral infections (coronavirus associated with severe acute respiratory syndrome ( SARS), rhinovirus (Rhinovirus), adenovirus (Adenovirus), respiratory syncytial virus (Pneumovirus) and parainfluenza virus (Paramyxovirus). According to the mechanism of antiviral action, it belongs to fusion inhibitors, interacts with the hemagglutinin of the virus and prevents the fusion of the lipid membrane of the virus and cell membranes. It has interferon-inducing activity - in a study on mice, the induction of interferons was noted after 16 hours, and high titers of interferons remained in the blood up to 48 hours after administration. Stimulates cellular and humoral immune responses: increases the number of lymphocytes in the blood, especially T-cells (CD3), increases the number of T-helpers (CD4) without affecting the level of T-suppressors (CD8), normalizes the immunoregulatory index, stimulates the phagocytic function of macrophages and increases the number of natural killer (NK) cells.
Therapeutic effectiveness for viral infections is manifested in a decrease in the duration and severity of the disease and its main symptoms, as well as in a decrease in the incidence of complications associated with viral infection and exacerbations of chronic bacterial diseases.
Refers to low-toxic drugs (LD50>4 g/kg). Does not have any negative effects on the human body when administered orally in recommended doses. Pharmacokinetics. Quickly absorbed and distributed throughout organs and tissues. The maximum concentration in blood plasma when taking the drug at a dose of 200 mg of umifenovir is achieved after 1 hour, the volume of distribution (Vd) is 1432 l. Metabolized in the liver. The half-life averages 11 hours. About 40% is excreted unchanged, mainly in the bile (38.9%) and, in small quantities, in the kidneys (0.12%). During the first day, 90% of the administered dose is eliminated. Pregnancy and breastfeeding The use of Arbidol® during pregnancy is contraindicated. It is not known whether the active substance of Arbidol® or its metabolites passes into breast milk in women during lactation. If it is necessary to use the drug Arbidol®, you should stop breastfeeding. Conditions for dispensing from pharmacies Without a prescription. Side effects Allergic reactions: rarely (with a frequency of at least 1/10000, but less than 1/1000) - skin itching, rash, angioedema, urticaria; very rarely (with a frequency of less than 1/10,000) - anaphylactic reactions.
If any of the side effects indicated in the instructions get worse, or you notice any other side effects not listed in the instructions, tell your doctor. Special instructions When prescribing to patients with diabetes mellitus, as well as on a low-calorie diet, it is necessary to take into account that the suspension contains sucrose (0.8 g/5 ml or 0.06 XE/5 ml). It is necessary to follow the regimen and duration of taking the drug recommended in the instructions. If you miss taking one dose of the drug, the missed dose should be taken as early as possible and continue the course of taking the drug according to the started regimen.
When calculating the amount of suspension required for a course of administration, it is necessary to take into account the shelf life of the prepared suspension, which is 10 days. A course of treatment for the indication of nonspecific prophylaxis during an epidemic of influenza and other acute respiratory viral infections in children from 2 to 6 years of age will require two bottles of the drug Arbidol®. It does not exhibit central neurotropic activity and can be used in medical practice by people of various professions, incl. requiring increased attention and coordination of movements (transport drivers, operators, etc.). Storage conditions Store at a temperature not exceeding 25 C.
Store the prepared suspension at a temperature not exceeding 8 C (in the refrigerator). Do not freeze.
Keep out of the reach of children. Directions for use and dosage: Orally, before meals.
Preparation of the suspension.
Add 30 ml (or approximately 2/3 of the bottle volume) of boiled water and cooled to room temperature to the bottle containing the powder. Close the bottle with a lid, turn it upside down and shake thoroughly until a homogeneous suspension is obtained. Add boiled and cooled water to a volume of 100 ml (up to the mark on the bottle) and shake again. Before each dose, shake the contents of the bottle thoroughly until a homogeneous suspension is obtained. Measure a single dose using the included measuring spoon.
Single dose (depending on age): from 2 to 6 years - 10 ml (50 mg) from 6 to 12 years - 20 ml (100 mg) over 12 years and adults - 40 ml (200 mg) Dosage regimens:
Nonspecific prophylaxis during an epidemic of influenza and other acute respiratory viral infections in a single dose 2 times a week for 3 weeks.
Nonspecific prophylaxis in direct contact with patients with influenza and other acute respiratory viral infections in a single dose once a day for 10-14 days.
Treatment of influenza and other acute respiratory viral infections with an uncomplicated course in a single dose 4 times a day (every 6 hours) for 5 days.
Complex therapy of acute intestinal infections of rotavirus etiology in a single dose 4 times a day (every 6 hours) for 5 days.
For nonspecific prevention and treatment of severe acute respiratory syndrome (SARS):
For nonspecific prevention of SARS (upon contact with a patient) in children from 6 years of age and adults: children from 6 to 12 years of age - 20 ml (100 mg), children over 12 years of age and adults - 40 ml (200 mg) once a day. within 12-14 days.
For the treatment of SARS in children over 12 years of age and adults: children over 12 years of age and adults – 40 ml (200 mg) 2 times a day for 8-10 days.
Release form, composition
Arpetol is available in white coated tablets with a biconvex surface. Each tablet contains: umifenovir hydrochloride – 50 mg or 100 mg; as well as excipients: povidone (K 17), microcrystalline cellulose, modified corn starch (Starch 1500), magnesium stearate, colloidal anhydrous silicon dioxide, lactose monohydrate, opadry II white (polyvinyl alcohol, titanium dioxide, polyethylene glycol, talc).
In pharmacies, arpetol is sold in blister packs of 10, 15 or 20 tablets (a cardboard pack can contain from 10 to 40 tablets).
pharmachologic effect
Arpetol is an antiviral agent, has an immunomodulatory and anti-influenza effect, specifically suppresses viruses type A and B, coronavirus associated with severe acute respiratory syndrome (SARS). Prevents the contact and penetration of viruses into the cell, suppressing the fusion of the lipid shell of the virus with cell membranes. Arpetol has an interferon-inducing effect, stimulates humoral and cellular immune responses, the phagocytic function of macrophages, and increases the body's resistance to viral infections. Umifenovir reduces the incidence of complications associated with viral infection, as well as exacerbations of chronic bacterial diseases.
Therapeutic effectiveness for viral infections is manifested in a decrease in the severity of general intoxication and clinical phenomena, and a reduction in the duration of the disease.
Arpetol is a low-toxic drug. Does not have any negative effects on the human body when administered orally in recommended doses.
Umifenovir is quickly absorbed and distributed to organs and tissues. The maximum concentration in blood plasma when taken at a dose of 50 mg is achieved after 1.2 hours, at a dose of 100 mg - after 1.5 hours. Metabolized in the liver. The half-life is 17-21 hours. About 40% is excreted unchanged, mainly with bile (38.9%) and in small amounts by the kidneys (0.12%). During the first day, 90% of the administered dose is eliminated.
Instructions for use of arpetol and dose
Before using this medicine, consult your doctor.
Arpetol is taken orally, before meals. Single dose: children from 3 to 6 years old - 50 mg, from 6 to 12 years old - 100 mg, over 12 years old and adults - 200 mg (2 tablets of 100 mg or 4 tablets of 50 mg).
For nonspecific prophylaxis
- In direct contact with patients with influenza and other acute respiratory viral infections: - from 3 to 6 years of age - 50 mg, from 6 to 12 years - 100 mg, over 12 years and adults - 200 mg once a day for for 10-14 days.
- To prevent exacerbations of chronic bronchitis, relapse of herpes infection during an influenza epidemic and other acute respiratory viral infections: - from 3 to 6 years - 50 mg, from 6 to 12 years - 100 mg, over 12 years and adults - 200 mg. twice a week for 3 weeks.
- For the prevention of severe acute respiratory syndrome (in contact with patients): - children from 6 to 12 years old, 100 mg, over 12 years old, 200 mg once a day (before meals), up to 12-14 days.
- Prevention of postoperative complications: - from 3 to 6 years - 50 mg, from 6 to 12 years - 100 mg, from 12 years old and adults - 200 mg 2 days before surgery, then on days 2 and 5 after surgery.
For treatment
- Influenza, other acute respiratory viral infections without complications: - from 3 to 6 years - 50 mg, from 6 to 12 years - 100 mg, from 12 years - 200 mg 4 times a day (every 6 hours) for 5 days.
- Influenza, other acute respiratory viral infections with the development of complications (bronchitis, pneumonia, etc.): - from 3 to 6 years - 50 mg, from 6 to 12 years - 100 mg, from 12 years and adults - 200 mg 4 once a day (every 6 hours) for 5 days, then a single dose once a week for 4 weeks.
- Severe acute respiratory syndrome: - from 12 years of age and adults - 200 mg 2 times a day for 8-10 days.
- In the complex treatment of chronic bronchitis, herpetic infection: - from 3 to 6 years - 50 mg, from 6 to 12 years - 100 mg, from 12 years and adults - 200 mg 4 times a day (every 6 hours) for 5-7 days, then a single dose 2 times a week for 4 weeks.
- Complex therapy of acute intestinal infections of rotavirus etiology in children over 3 years of age: - children from 3 to 6 years old - 50 mg, from 6 to 12 years old - 100 mg, from 12 years old - 200 mg 4 times a day (every 6 hours ) up to 5 days.
If you have any doubts or questions, contact your healthcare provider.
